Security Snapshot

RELMADA THERAPEUTICS, INC. - Common stock, $0.001 par value per share (RLMD) Institutional Ownership

CUSIP: 75955J402

13F Institutional Holders and Ownership History from Q4 2019 to Q2 2026

Latest Period

Q2 2026

Institutions Reporting

127

Shares (Excl. Options)

100,952,229

Price

$6.92

Save this security page for your next review

Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.

Latest holder snapshot 5 signals
Portfolio coverage rank
0.01%
Share change
+16,121,772
Value change
+$111,452,685
Number of holders
127
Issuer context Names, identifiers, and filing context for this profile. 3 identity fields
Shares outstanding
105,000,000
SEC-reported price per share
$5.20
Insider filing price
$5.20
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors

Key facts

  • RLMD - RELMADA THERAPEUTICS, INC. - Common stock, $0.001 par value per share is tracked under CUSIP 75955J402.
  • 127 institutions reported positions in Q2 2026.
  • 9 significant owners is listed from Schedule 13D/13G reporting.

Change

  • Holder count moved from 102 to 127 between Q1 2026 and Q2 2026.
  • SEC-reported value moved from $588,840,510 to $698,607,614.

Research use

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Evidence

Source: SEC Form 13F

Latest holder context comes from 127 institutions filings for Q2 2026.

Open SEC evidence

Security key

75955J402

Latest holder period

Q2 2026

13F holders

127

13D/G owners

9

CIK / CUSIP context first

13D/G owners

Significant owners

Large-stake holder rows connected to Schedule 13D/G evidence.

Rows
9
Security
RLMD
Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
JANUS HENDERSON GROUP PLC 10% $35,932,374 7,439,415 JANUS HENDERSON GROUP PLC 30 Jan 2026
BlackRock, Inc. 7% $50,882,158 7,352,913 BlackRock, Inc. 30 Jun 2026
Squadron Capital Management LLC 7% -29% $47,113,500 -$291,719 7,350,000 -0.62% Squadron Master Fund LP 30 Jun 2026
Venrock Healthcare Capital Partners III, L.P. 6.2% $46,925,802 6,508,433 Venrock Healthcare Capital Partners III, L.P. 02 Jun 2026
Commodore Capital LP 5.1% $40,630,789 5,505,527 Commodore Capital LP 27 Apr 2026
Adage Capital Management, L.P. 4.5% -21% $35,152,106 +$3,639,506 4,763,158 +12% Adage Capital Management, L.P. 31 Mar 2026
MILLENNIUM MANAGEMENT LLC 4.4% $28,960,816 4,567,952 Millennium Management LLC 16 Jun 2026
Spruce Street Capital LP 5.6% $17,284,546 4,086,181 Spruce Street Capital LP 31 Dec 2025
Ikarian Capital, LLC 4.8% $7,122,152 3,543,359 Ikarian Capital, LLC 30 Sep 2025

As of 30 Jun 2026, 127 institutional investors reported holding 100,952,229 shares of RELMADA THERAPEUTICS, INC. - Common stock, $0.001 par value per share (RLMD). This represents 96% of the company’s total 105,000,000 outstanding shares.

13F concentration

Top 25 institutional shareholders

Largest 13F positions for this security by reported shares and value.

Top holder share
79%
Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
Jupiter Topco LLC 11% 11,164,803 0% 0.03% $77,316,261
BlackRock, Inc. 7.1% 7,426,780 +476% 0% $51,393,319
Squadron Capital Management LLC 7% 7,350,000 -13% 17% $50,862,000
Venrock Adviser, LLC 6.5% 6,844,305 +41% 1.4% $47,362,591
Spruce Street Capital LP 6.1% 6,391,328 +2.1% 8.7% $44,227,990
ADAGE CAPITAL PARTNERS GP, L.L.C. 4.5% 4,763,158 0% 0.05% $32,961,053
VANGUARD CAPITAL MANAGEMENT LLC 4.2% 4,460,210 +45% 0% $30,864,653
Jones Hill Capital LP 3.5% 3,655,075 +966% 5.4% $25,293,119
ORBIMED ADVISORS LLC 3.5% 3,631,195 -23% 0.48% $25,127,869
STATE STREET CORP 2.4% 2,517,550 +605% 0% $17,421,446
GEODE CAPITAL MANAGEMENT, LLC 2.4% 2,492,573 +194% 0% $17,253,429
MILLENNIUM MANAGEMENT LLC 2.2% 2,361,827 -40% 0.01% $16,343,843
MARSHALL WACE, LLP 2.1% 2,246,839 -50% 0.01% $15,548,126
Ikarian Capital, LLC 2% 2,148,359 -20% 2.4% $14,866,644
Driehaus Capital Management LLC 2% 2,132,053 0% 0.09% $14,753,807
AMERIPRISE FINANCIAL INC 1.8% 1,937,972 +22% 0% $13,410,767
EVENTIDE ASSET MANAGEMENT, LLC 1.8% 1,858,416 +121% 0.17% $12,860,239
Balyasny Asset Management L.P. 1.4% 1,520,688 +502% 0.02% $10,523,161
STEMPOINT CAPITAL LP 1.4% 1,460,093 +144% 1.7% $10,103,844
Commodore Capital LP 1.4% 1,425,000 +125% 0.59% $9,861,000
Polar Capital Holdings Plc 1.3% 1,340,428 -5.2% 0.03% $9,275,762
CITADEL ADVISORS LLC 1% 1,061,665 0% $7,346,722
Sio Capital Management, LLC 0.96% 1,003,562 +4% 1.2% $6,944,649
Opaleye Management Inc. 0.89% 935,000 0% 0.59% $6,470,200
VANGUARD PORTFOLIO MANAGEMENT LLC 0.86% 898,198 0% $6,215,530

Quarter history

Institutional holders across reporting periods

Holder count, reported shares/value, and median price by quarter.

Periods
27
Latest
Q2 2026
Rows shown
1-25 of 27
Period 13F Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q2 100,952,229 $698,607,614 +$111,452,685 $6.92 127
2026 Q1 84,720,353 $588,840,510 +$220,722,088 $6.96 102
2025 Q4 50,901,642 $245,749,015 +$155,594,501 $4.83 77
2025 Q3 7,739,580 $15,541,689 +$5,248,275 $2.01 43
2025 Q2 5,303,151 $3,177,608 -$311,761 $0.60 48
2025 Q1 6,219,491 $1,678,348 -$765,348 $0.27 43
2024 Q4 8,399,225 $4,362,564 -$9,886,723 $0.52 48
2024 Q3 12,376,687 $40,240,571 -$3,630,516 $3.24 69
2024 Q2 13,555,167 $40,671,232 -$3,047,999 $3.00 78
2024 Q1 14,295,630 $66,487,069 +$3,440,282 $4.65 90
2023 Q4 13,621,440 $56,386,775 -$3,313,848 $4.14 83
2023 Q3 14,992,668 $44,979,292 -$3,168,578 $3.00 87
2023 Q2 16,099,667 $39,628,526 -$4,052,287 $2.46 91
2023 Q1 17,764,331 $40,142,172 -$4,573,760 $2.26 87
2022 Q4 19,144,470 $66,816,077 -$456,735,123 $3.49 106
2022 Q3 25,783,847 $954,470,507 +$46,796,895 $37.02 131
2022 Q2 24,632,853 $467,785,642 +$33,496,825 $18.99 106
2022 Q1 23,069,358 $622,305,579 +$69,498,228 $26.99 107
2021 Q4 20,739,885 $467,189,248 +$239,138,409 $22.53 91
2021 Q3 10,023,314 $262,675,920 -$4,620,967 $26.21 81
2021 Q2 9,944,006 $318,306,821 +$11,580,961 $32.01 83
2021 Q1 9,536,264 $335,739,251 +$3,534,612 $35.21 81
2020 Q4 9,311,019 $298,677,225 -$48,362,964 $32.07 79
2020 Q3 10,443,239 $392,874,164 -$4,538,306 $37.62 72
2020 Q2 10,506,228 $469,323,200 +$57,833,259 $44.75 74
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .